Dr. Ghamande on the AIM2CERV Trial in Cervical Cancer

In Partnership With:

Partner | Cancer Centers | <b>Augusta University Georgia Cancer Center</b>

Sharad Ghamande, MD, associate professor, Georgia Cancer Center, Augusta University, discusses the AIM2CERV trial for patients with cervical cancer.

Sharad Ghamande, MD, associate professor, Georgia Cancer Center, Augusta University, discusses the AIM2CERV trial for patients with cervical cancer.

According to Ghamande, the standard of care used to be radiation therapy with external and internal radiation. However, 5 years ago the addition of chemotherapy made a large difference in response rates and overall survival.

Patients with stage II advanced cervical cancer had a disease-free survival of 69% at 3 years. To date, there has not been a big difference made in these numbers, explains Ghamande.

The phase III AIM2CERV study is investigating axalimogene filolisbac (ADXS11-001) as an upfront therapy evaluating its ability to consolidate these patients who are destined to fail, and potentially prevent cervical cancer. Patients on this trial are randomized to ADXS11-001 or a placebo. This is a global trial with 150 sites in over 20 countries.